$23.48
2.17% yesterday
NYSE, Jun 13, 10:00 pm CET
ISIN
IT0005452658
Symbol
STVN
Industry

Stevanato Group Spa Stock price

$23.48
-0.94 3.85% 1M
+0.17 0.73% 6M
+1.69 7.76% YTD
+5.18 28.31% 1Y
+3.81 19.37% 5Y
+3.81 19.37% 10Y
+3.81 19.37% 20Y
NYSE, Closing price Fri, Jun 13 2025
-0.52 2.17%
ISIN
IT0005452658
Symbol
STVN
Industry

Key metrics

Market capitalization $6.55b
Enterprise Value $6.93b
P/E (TTM) P/E ratio 47.06
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.42
P/S ratio (TTM) P/S ratio 5.12
P/B ratio (TTM) P/B ratio 4.03
Dividend yield 0.26%
Last dividend (FY24) $0.06
Revenue growth (TTM) Revenue growth 1.72%
Revenue (TTM) Revenue $1.28b
EBIT (operating result TTM) EBIT $208.71m
Free Cash Flow (TTM) Free Cash Flow $-182.48m
Cash position $113.50m
EPS (TTM) EPS $0.51
P/E forward 41.17
P/S forward 4.89
EV/Sales forward 5.17
Short interest 4.79%
Show more

Is Stevanato Group Spa a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Stevanato Group Spa Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Stevanato Group Spa forecast:

9x Buy
75%
3x Hold
25%

Analyst Opinions

12 Analysts have issued a Stevanato Group Spa forecast:

Buy
75%
Hold
25%

Financial data from Stevanato Group Spa

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1,275 1,275
2% 2%
100%
- Direct Costs 909 909
7% 7%
71%
366 366
9% 9%
29%
- Selling and Administrative Expenses 120 120
4% 4%
9%
- Research and Development Expense 33 33
9% 9%
3%
224 224
16% 16%
18%
- Depreciation and Amortization 15 15
7% 7%
1%
EBIT (Operating Income) EBIT 209 209
16% 16%
16%
Net Profit 136 136
19% 19%
11%

In millions USD.

Don't miss a Thing! We will send you all news about Stevanato Group Spa directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Stevanato Group Spa Stock News

Neutral
Seeking Alpha
about one month ago
Stevanato Group S.p.A. (NYSE:STVN ) Q1 2025 Results Conference Call May 8, 2025 8:30 AM ET Company Participants Lisa Miles - SVP & Investor Relations Franco Stevanato - Chairman & Chief Executive Officer Marco Dal Lago - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Paul Knight - KeyBanc Michael Ryskin - Bank of America David Windley - Jefferies Tejas Savant - ...
Neutral
Business Wire
about one month ago
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in three upcoming investor conferences. Wednesday, May 14, 2025, at 5:00 p.m. (PT) – Fireside chat at the 2025 Bank of Americ...
Neutral
Business Wire
about one month ago
PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of...
More Stevanato Group Spa News

Company Profile

Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates in Biopharmaceutical and Diagnostic Solutions and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy.

Head office Italy
CEO Franco Stevanato
Employees 5,635
Founded 1996
Website www.stevanatogroup.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today